Patients receiving IMRT and three-dimensional conformal radiotherapy appear to have similar rates of developing secondary cancer

Similar findings seen for those who previously used combustible cigarettes and currently use electronic cigarettes

Improved progression-free survival seen for amivantamab-lazertinib versus osimertinib as first-line treatment

Increase in UTD-LCS prevalence seen with age and number of comorbidities; relatively lower levels seen in Southern states

Uptake of lung cancer screening was low, but overall and lung cancer-specific survival improved with screening

PFS benefit seen in most subgroups, including those whose disease progressed while receiving third-generation EGFR-TKIs

Significantly longer progression-free survival, but not overall survival, seen for osimertinib in unresectable EGFR-mutation NSCLC

Drug approved for patients with ALK-positive, early-stage cancer who undergo surgery to remove their tumor

Findings seen among patients with resected ALK-positive non-small cell lung cancer